These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37976756)

  • 1. Immune checkpoint inhibitors with chemotherapy for primary advanced mismatch repair-deficient endometrial cancer: A cost-effectiveness analysis.
    Kim J; Lim J; Lee SW; Park JY; Suh DS; Kim JH; Kim YM; Kim DY
    Gynecol Oncol; 2023 Dec; 179():106-114. PubMed ID: 37976756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dostarlimab for recurrent mismatch repair-deficient endometrial cancer: A cost-effectiveness study.
    Dioun S; Chen L; Melamed A; Gockley A; St Clair CM; Hou JY; Khoury-Collado F; Hur C; Elkin E; Accordino M; Hershman DL; Wright JD
    BJOG; 2023 Jan; 130(2):214-221. PubMed ID: 36330672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer.
    Huo G; Song Y; Liu W; Guo H; Chen P
    Front Pharmacol; 2024; 15():1391896. PubMed ID: 38966552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysis.
    Liu K; Zhu Y; Zhou Y; Zhang Y; Zhu H
    Gynecol Oncol; 2022 Sep; 166(3):582-588. PubMed ID: 35781166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy.
    Dioun S; Chen L; De Meritens AB; St Clair CM; Hou JY; Khoury-Collado F; Pua T; Hershman DL; Wright JD
    Gynecol Oncol; 2024 Mar; 182():70-74. PubMed ID: 38262241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of pembrolizumab plus chemotherapy for advanced endometrial cancer.
    Huo G; Song Y; Chen P
    J Gynecol Oncol; 2024 Apr; ():. PubMed ID: 38606826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer.
    You M; Zeng X; Zhang J; Huang Y; Zhang Y; Cai Z; Hu Y
    Front Immunol; 2023; 14():1267322. PubMed ID: 37731489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy plus chemotherapy in patients with advanced endometrial cancer: a cost-effectiveness analysis.
    Zhu Y; Liu K; Zhu H
    J Gynecol Oncol; 2024 Jun; ():. PubMed ID: 38857909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of pembrolizumab plus lenvatinib compared with chemotherapy for treating previously treated advanced endometrial cancer in Sweden.
    Ralph L; Young K; Upadhyay N; Prabhu VS; Ljungcrantz C; Massaad R; Xu R; Giertz A; Merchant A; Orlowski R; Duska L
    J Med Econ; 2024; 27(1):483-491. PubMed ID: 38470404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer.
    Thurgar E; Gouldson M; Matthijsse S; Amonkar M; Marinello P; Upadhyay N; Nwankwo C; Aguiar-Ibáñez R
    J Med Econ; 2021; 24(1):675-688. PubMed ID: 33866938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis.
    Ackroyd SA; Huang ES; Kurnit KC; Lee NK
    Gynecol Oncol; 2021 Aug; 162(2):249-255. PubMed ID: 34103196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer.
    Shi Y; Chen J; Shi B; Liu A
    Gynecol Oncol; 2022 Feb; 164(2):379-385. PubMed ID: 34920886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis.
    Feng M; Chen Y; Yang Y; Li Q
    Front Public Health; 2022; 10():881034. PubMed ID: 35619813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenvatinib plus pembrolizumab in the patients with advanced previously treated endometrial cancer: A cost-effectiveness analysis in the United States and in China.
    Liao X; Wu Y; Lin D; Gu D; Luo S; Huang X; Xu X; Weng X; Lin S
    J Obstet Gynaecol Res; 2024 May; 50(5):881-889. PubMed ID: 38485235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system.
    Zhu C; Han G; Wu B
    BMC Health Serv Res; 2023 Oct; 23(1):1083. PubMed ID: 37821934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.
    Barrington DA; Haight PJ; Calhoun C; Tubbs C; Cohn DE; Bixel KL
    Gynecol Oncol; 2021 Sep; 162(3):626-630. PubMed ID: 34148720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer in China.
    Zheng Z; Yang L; Xu S; Zhu H; Cai H
    Front Pharmacol; 2022; 13():944931. PubMed ID: 36249813
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness analysis of pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer.
    Liu T; Liu S; Guan S; Tai Y; Jin Y; Dong M
    J Chemother; 2023 Dec; 35(8):745-752. PubMed ID: 36591729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of pembrolizumab in patients with treatment-refractory metastatic colorectal cancer in Japan.
    Sugiura K; Hiratsuka H; Oshima G; Aiko S
    Jpn J Clin Oncol; 2023 Jul; 53(8):691-697. PubMed ID: 37259600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
    Courtney PT; Yip AT; Cherry DR; Salans MA; Kumar A; Murphy JD
    JAMA Netw Open; 2021 May; 4(5):e218787. PubMed ID: 33938936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.